This observational study will evaluate the safety, efficacy, quality of life and predictive/selection factors for Avastin (bevacizumab) in combination with carboplatin/paclitaxel in first line in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in clinical practice. Data of eligible patients will be collected during up to 15 months of treatment and 12 months of follow-up. A second recruitment phase has been opened to focus on patients \>/= 70 years.
Study Type
OBSERVATIONAL
Enrollment
1,090
Ortenau Klinikum Offenburg; Med. Klinik II; Mammachirurgie und Gynäkologisch-Onkologische Chirurgie
Offenburg, Germany
Efficacy: Progression-free survival
Time frame: up to approximately 27 months
Safety: Incidence of adverse events
Time frame: approximately 5 years
Quality of life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30/QLQ-OV28 questionnaires
Time frame: up to approximately 27 months
Selection criteria for first-line treatment with Avastin and carboplatin/paclitaxel: clinical/demographic patient characteristics
Time frame: approximately 5 years
Treatment discontinuations/modifications
Time frame: approximately 5 years
Treatment duration
Time frame: approximately 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.